Medtronic (MDT) is back in focus after initiating a voluntary Class II recall of its DLP One-Piece Pediatric Arterial Cannula, following two complaints about loose foreign material containing trace levels of blood.

At a share price of US$84.22, Medtronic's recent 1 month share price return of 4.0% contrasts with a year to date share price return that is down 12.3%, while the 3 year total shareholder return of 5.9% points to relatively modest longer term progress as investors weigh product recall headlines against broader expectations for the business.

If this kind of healthcare news has your attention, it can be useful to see what else is moving in related areas and uncover 41 healthcare AI stocks

For Medtronic, a 4.0% move over the past month against a weaker year to date picture raises a straightforward question: are you seeing a business story starting to reassert itself, or just sentiment adjusting around recall headlines as you assess valuation next?

Most Popular Narrative: 6.8% Undervalued

Medtronic's most followed narrative currently points to a fair value of $90.37 per share, compared with the last close at $84.22. This frames the recent recall headlines against a modest valuation gap.

Diversification in my portfolio meant investing in the healthcare sector. I already owned Pfizer. Functional and technical analysis showed Medtronic plc to be a good addition for the longer term. Actual indicators for this moment: P/E fwd ~13.5, PEG ~1.6, Debt/Equity ~57%, EPS ~11%, Payout ~76%, and Operational Cash Flow approx. $7.3 billion. MACD above signal line, RSI 54.26, MOM and OBV positive. Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio. Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable. My investment horizon is 5 to 10 years. Medtronic plc is not spectacular in its growth but does grow over the long term. Medtronic plc is a dividend aristocrat. The number of years of dividend growth is 50 years. I cautiously bought a small group of 5 shares to monitor it more closely and potentially invest further. The healthcare weighting in my portfolio is now 2%.

Curious how a long term horizon, steady growth assumptions, dividend history, and margin expectations come together to reach that fair value for Medtronic? The full narrative walks through the earnings and cash flow profile behind that price tag, and how those inputs justify a small undervaluation gap without relying on aggressive projections.

Result: Fair Value of $90.37 (UNDERVALUED)

However, Medtronic's voluntary recall and any change in healthcare procedure volumes could challenge the thesis, especially if they weigh on revenue growth or profit margins.

Next Steps

If the mixed sentiment around Medtronic has you thinking, this is the moment to review the numbers yourself and move beyond headlines. To understand why some investors are still optimistic, take a closer look at the 5 key rewards

Looking for more investment ideas beyond Medtronic?

If Medtronic has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas that match how you like to invest.

• Target income first and review companies that may support regular cash returns through the 8 dividend fortresses
• Spot potential bargains early by checking out the screener containing 20 high quality undiscovered gems
• Prioritise resilience and stress test your portfolio with the 84 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.